Malak Bio

Malak Bio is an early-stage biotechnology company based in San Diego, California, focused on the discovery and development of novel small molecule therapeutics for oncology. The company specializes in targeting the CD47-SIRPalpha axis, a critical immune checkpoint pathway that cancer cells exploit to evade detection by the innate immune system. By developing highly selective small molecule inhibitors, Malak Bio aims to overcome the limitations of existing antibody-based therapies, such as poor tumor penetration and off-target toxicities like anemia. Their approach leverages a proprietary platform to identify potent candidates that can restore the phagocytic activity of macrophages against tumor cells. Currently, the company's programs are in the pre-clinical stage, targeting a variety of solid and hematologic cancers.